cetuximab,encorafenib,binimetinib,fruquintinib
pfizer,hutchmed,eli lilly,array biopharma
['fresco2', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'beacon']
 discussing the #fresco2 trial and acquired resistance in the #beacon study in #mcrc at #esmo22 
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma